At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Pre-Market Trading 05-17 07:04:40 EDT
24.36
-0.36
-1.46%
High25.62Low23.99Vol19.94K
Open24.33D1 Closing24.72Amplitude6.59%
Mkt Cap201.06MTradable Cap60.08MTotal Shares8.25M
T/O486.68KT/O Rate0.81%Tradable Shares2.47M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), Prestige Consumer Healthcare (PBH) and CervoMed (CRVO)
TIPRANKS  ·  05-16 18:50
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), Prestige Consumer Healthcare (PBH) and CervoMed (CRVO)
CervoMed GAAP EPS of -$0.41 beats by $0.01, revenue of $2.35M beats by $0.35M
seekingalpha  ·  05-15 20:59
CervoMed GAAP EPS of -$0.41 beats by $0.01, revenue of $2.35M beats by $0.35M
CervoMed Q1 EPS $(0.41) Misses $(0.39) Estimate, Sales $2.35M Beat $1.35M Estimate
Benzinga  ·  05-15 20:14
CervoMed Q1 EPS $(0.41) Misses $(0.39) Estimate, Sales $2.35M Beat $1.35M Estimate
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire  ·  05-15 12:00
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
CervoMed Inc reports results for the quarter ended in March - Earnings Summary
Reuters  ·  05-15 06:22
CervoMed Inc reports results for the quarter ended in March - Earnings Summary
BRIEF-CervoMed Files Prospectus Related To Resale By Selling Stockholders Of Up To 5.1 Mln Shares
Reuters  ·  05-11
BRIEF-CervoMed Files Prospectus Related To Resale By Selling Stockholders Of Up To 5.1 Mln Shares
CervoMed Inc expected to post a loss of 39 cents a share - Earnings Preview
Reuters  ·  05-10
CervoMed Inc expected to post a loss of 39 cents a share - Earnings Preview
CervoMed Updates Stakeholders on Clinical and Financial Status
TIPRANKS  ·  04-23
CervoMed Updates Stakeholders on Clinical and Financial Status
CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24…
Zacks Small Cap Research  ·  04-10
CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24…
CervoMed (NASDAQ:CRVO) Price Target Raised to $65.00 at Canaccord Genuity Group
Defense World  ·  04-09
CervoMed (NASDAQ:CRVO) Price Target Raised to $65.00 at Canaccord Genuity Group
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
TIPRANKS  ·  04-08
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
CervoMed Shares Operational and Financial Insights Online
TIPRANKS  ·  04-04
CervoMed Shares Operational and Financial Insights Online
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
GlobeNewswire  ·  04-02
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
seekingalpha  ·  04-02
CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
CervoMed GAAP EPS of -$0.82 beats by $1.23, revenue of $7.14M beats by $3.09M
seekingalpha  ·  04-01
CervoMed GAAP EPS of -$0.82 beats by $1.23, revenue of $7.14M beats by $3.09M
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
GlobeNewswire  ·  04-01
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
Cervomed Inc. Braces for Impact: How Political Uncertainty and the Presidential Election Could Shake Up the Pharma Industry
TIPRANKS  ·  03-31
Cervomed Inc. Braces for Impact: How Political Uncertainty and the Presidential Election Could Shake Up the Pharma Industry
CervoMed Inc reports results for the quarter ended in December - Earnings Summary
Reuters  ·  03-30
CervoMed Inc reports results for the quarter ended in December - Earnings Summary
CervoMed Inc expected to post a loss of 21 cents a share - Earnings Preview
Reuters  ·  03-30
CervoMed Inc expected to post a loss of 21 cents a share - Earnings Preview
BRIEF-CervoMed Announces Up To $149.4 Mln Private Placement Financing
Reuters  ·  03-28
BRIEF-CervoMed Announces Up To $149.4 Mln Private Placement Financing

Introduction

Company Name.
CervoMed
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Issue price:
--